Joining forces in the battle against cancer, myocardial infarction or Alzheimer’s disease
09/10/2007 | Our company
Together with the German Federal Ministry of Research and Education, five German pharmaceutical and medical device companies are starting the “Technology Initiative Molecular Imaging“
Early detection of cancer, Alzheimer’s or cardiovascular diseases, effective therapies and greater efficiency throughout the healthcare system – these are the key goals of the “Technology Initiative - Molecular Imaging” which was set forth today by five leading pharmaceutical and medical device companies as well as the German Federal Ministry of Research and Education (BMBF).
Bayer Schering Pharma, Boehringer Ingelheim Pharma, Siemens Medical Solutions, Karl Storz and Carl Zeiss will spend a total of 750 million Euros during the next ten years for the development of new methods in molecular imaging. In the next six years, BMBF will also promote cooperative R&D projects in the amount of 150 million Euros.